Takeda ditches late-stage Ninlaro trial
The company remains “optimistic about Ninlaro and continue to investigate Ninlaro in patient populations across the continuum of multiple myeloma care”.
Read More
Tag: Data Monitoring Committee
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
